论文部分内容阅读
目的观察他莫昔芬片、莱曲唑内分泌治疗乳腺癌过程中,不良反应引起骨质疏松的差异。方法对绝经后60例乳腺癌患者,随机抽取30例口服他莫昔芬片,30例口服莱曲唑片,分别测口服药0、1、2年时每例患者的骨密度,进行统计学分析。结果口服他莫昔芬片、莱曲唑片1、2年测得骨密度值分别为(0.965±0.021)、(0.923±0.017)、(0.915±0.019)、(0.896±0.013)g/cm2。结论口服他莫昔芬片、莱曲唑片都可使骨密度减低,用药时间越长,骨密度减低越明显;口服莱曲唑片骨密度减低比口服他莫昔芬片使骨密度减低更明显。
Objective To observe the differences of osteoporosis caused by adverse reactions during the treatment of breast cancer with tamoxifen tablets and letrozole endocrine. Methods Sixty patients with breast cancer were randomly divided into two groups. Twenty patients were randomized to receive tamoxifen and 30 patients were given oral leflunomide. The bone mineral density (BMD) of each patient at 0, 1, analysis. Results The BMD values of oral tamoxifen tablets and letrozole tablets for 1 and 2 years were (0.965 ± 0.021), (0.923 ± 0.017), (0.915 ± 0.019) and (0.896 ± 0.013) g / cm2, respectively. Conclusion Oral tamoxifen tablets and letrozole tablets can reduce the bone mineral density, the longer the medication, the more obvious reduction of bone mineral density; oral letrozole reduced bone mineral density compared with oral tamoxifen tablets to reduce bone mineral density more obvious.